Union Bancaire Privee UBP SA Sells 2,144 Shares of Stryker Corporation $SYK

Union Bancaire Privee UBP SA lowered its holdings in Stryker Corporation (NYSE:SYK) by 31.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,592 shares of the medical technology company’s stock after selling 2,144 shares during the period. Union Bancaire Privee UBP SA’s holdings in Stryker were worth $1,619,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SYK. Clayton Financial Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the third quarter worth about $27,000. Elevation Point Wealth Partners LLC purchased a new stake in Stryker during the second quarter worth about $28,000. Kilter Group LLC bought a new stake in Stryker in the second quarter worth about $29,000. Finally, Howard Hughes Medical Institute purchased a new position in Stryker in the second quarter valued at about $29,000. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK opened at $335.96 on Friday. Stryker Corporation has a 52-week low of $328.23 and a 52-week high of $404.87. The stock’s 50-day simple moving average is $363.25 and its 200 day simple moving average is $366.04. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock has a market capitalization of $128.57 billion, a price-to-earnings ratio of 39.99, a price-to-earnings-growth ratio of 1.99 and a beta of 0.85.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the previous year, the firm earned $4.01 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is 41.90%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Robert W. Baird set a $437.00 target price on shares of Stryker in a research report on Friday, January 30th. Needham & Company LLC upped their price objective on Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Barclays reissued an “overweight” rating and set a $469.00 price objective on shares of Stryker in a report on Monday, February 2nd. Sanford C. Bernstein boosted their target price on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Stryker in a research report on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.